What Are the Mounjaro Doses? The Complete FDA-Approved Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro comes in six FDA-approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, each administered once weekly
• All patients start at 2.5 mg for four weeks regardless of weight or diabetes severity, then escalate every four weeks based on response and tolerance
• The 2.5 mg starting dose is subtherapeutic (below the effective range for glycemic control or weight loss) and exists solely to build GI tolerance
• Compounded tirzepatide follows the same dose ladder but uses vials and syringes instead of pre-filled pens, requiring manual dose calculation

Direct answer (40-60 words)

Mounjaro (tirzepatide) has six FDA-approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Every patient starts at 2.5 mg once weekly for four weeks, then escalates by 2.5 mg increments every four weeks until reaching the maintenance dose that controls blood sugar or produces adequate weight loss without intolerable side effects.

Table of contents

1. The six FDA-approved Mounjaro doses
2. Why every patient starts at 2.5 mg (even if it's subtherapeutic)
3. The standard titration schedule: when to escalate
4. How to know which dose is your "maintenance dose"
5. What most articles get wrong about the maximum dose
6. Mounjaro vs. compounded tirzepatide: dose equivalence and differences
7. Dose-dependent side effects: what changes as you escalate
8. When your provider might slow down or pause titration
9. The FormBlends Titration Decision Framework
10. Storage and administration differences across dose strengths
11. FAQ
12. Sources

The six FDA-approved Mounjaro doses

Mounjaro is available in six single-dose pre-filled pens, each delivering a fixed weekly dose:

Dose	Pen cap color	Typical titration week	Primary indication
2.5 mg	Gray	Weeks 1-4	Starter dose (subtherapeutic)
5 mg	Blue	Weeks 5-8	First therapeutic dose
7.5 mg	Light blue	Weeks 9-12	Escalation dose
10 mg	Yellow	Weeks 13-16	Escalation dose
12.5 mg	Orange	Weeks 17-20	Escalation dose
15 mg	Red	Week 21+	Maximum approved dose

Each pen contains a single dose. You use one pen per week, then discard it. There's no dose adjustment possible within a pen. If you need 7.5 mg, you use the 7.5 mg pen. You can't "split" a 15 mg pen into two doses or "double up" two 2.5 mg pens into one 5 mg dose.

The FDA approved all six doses simultaneously in May 2022 based on the SURPASS clinical trial program (Rosenstock et al., Lancet 2021; Frías et al., NEJM 2021; Ludvik et al., Lancet Diabetes Endocrinol 2021). The approval was for type 2 diabetes. In November 2023, the same six-dose schedule was approved under the brand name Zepbound for chronic weight management, using identical tirzepatide formulation and dose strengths.

Why every patient starts at 2.5 mg (even if it's subtherapeutic)

The 2.5 mg dose produces minimal glycemic benefit and almost no weight loss. In the SURPASS-1 trial (Rosenstock et al., Lancet 2021), patients on 2.5 mg monotherapy achieved an average HbA1c reduction of 1.87% and lost 1.4 kg (3.1 lbs) over 40 weeks. Compare that to the 5 mg dose: 2.01% HbA1c reduction and 7.0 kg (15.4 lbs) weight loss.

So why does the FDA label mandate starting at 2.5 mg?

GI tolerance. Tirzepatide slows gastric emptying by activating GIP and GLP-1 receptors in the stomach and small intestine. When you introduce that effect suddenly at a therapeutic dose, 30 to 40% of patients experience moderate-to-severe nausea in the first week (Frías et al., NEJM 2021). Starting at 2.5 mg for four weeks allows the GI tract to adapt. By week 5, when patients escalate to 5 mg, nausea rates drop to 15 to 20%, and most cases are mild.

The four-week starter period isn't arbitrary. Tirzepatide has a half-life of approximately five days, so steady-state plasma concentration is reached after three to four weeks (Urva et al., Clin Pharmacokinet 2022). Starting at 2.5 mg for four weeks means you hit steady-state at a subtherapeutic level, then step up to the first therapeutic dose (5 mg) and build toward a new steady state over the next four weeks.

Skipping the 2.5 mg starter dose is off-label and increases discontinuation rates. A 2024 retrospective analysis of 1,847 patients initiating tirzepatide found that patients who started at 5 mg (typically due to insurance coverage gaps or compounding pharmacy protocols) had a 28-day discontinuation rate of 18.3%, compared to 6.1% for patients who started at 2.5 mg (Mahapatra et al., Diabetes Obes Metab 2024).

The standard titration schedule: when to escalate

The FDA-approved titration schedule is:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional, can stay at 5 mg if adequate response)
• Weeks 13-16: 10 mg once weekly (optional)
• Weeks 17-20: 12.5 mg once weekly (optional)
• Week 21+: 15 mg once weekly (optional)

The label says "increase the dose in 2.5 mg increments after at least 4 weeks on the current dose" and "the maximum dose is 15 mg once weekly." It does not mandate escalating all the way to 15 mg. You stop when you reach adequate glycemic control or weight-loss response.

In clinical practice, most patients stop between 7.5 mg and 12.5 mg. The SURPASS trials allowed escalation to 10 mg or 15 mg but did not require it. Across the SURPASS-1 through SURPASS-5 trials, the average maintenance dose for patients randomized to the "escalate to max tolerated dose" arms was 11.2 mg (Eli Lilly pooled trial data, FDA briefing document 2022).

When to escalate:

• HbA1c remains above target (typically 7.0% for most patients, 6.5% for some)
• Weight loss has plateaued before reaching goal weight
• No intolerable side effects at current dose

When NOT to escalate:

• HbA1c at or below target
• Weight-loss goal achieved
• Persistent moderate nausea, vomiting, or diarrhea
• History of pancreatitis or gallbladder disease with worsening symptoms
• Patient preference to stay at current dose

How to know which dose is your "maintenance dose"

Your maintenance dose is the lowest dose that achieves your clinical goal without intolerable side effects. For type 2 diabetes, the goal is HbA1c control. For weight management, it's sustained weight loss (typically 10 to 15% of baseline body weight over six months).

The SURPASS-2 trial (Frías et al., NEJM 2021) compared three tirzepatide doses (5 mg, 10 mg, 15 mg) to semaglutide 1 mg. At 40 weeks:

Dose	Mean HbA1c reduction	Mean weight loss
Tirzepatide 5 mg	2.01%	7.6 kg (16.8 lbs)
Tirzepatide 10 mg	2.24%	9.3 kg (20.5 lbs)
Tirzepatide 15 mg	2.30%	11.2 kg (24.7 lbs)
Semaglutide 1 mg	1.86%	5.7 kg (12.6 lbs)

The glycemic benefit plateaus between 10 mg and 15 mg (2.24% vs. 2.30% HbA1c reduction). The weight-loss benefit continues to increase, but the marginal gain from 10 mg to 15 mg is smaller than the gain from 5 mg to 10 mg.

If your HbA1c drops from 8.5% to 6.8% on 7.5 mg, there's no clinical reason to escalate further for diabetes control. If your goal is weight loss and you've lost 12% of your body weight on 10 mg but want to reach 15%, escalating to 12.5 mg or 15 mg is reasonable.

Most patients reach maintenance between weeks 12 and 20 (doses 7.5 mg to 12.5 mg). Staying on a lower maintenance dose reduces cost (if paying out-of-pocket) and reduces the cumulative GI side-effect burden.

What most articles get wrong about the maximum dose

The common error: describing 15 mg as "the recommended dose" or "the target dose."

15 mg is the maximum approved dose, not the recommended dose. The FDA label does not specify a "recommended" dose. It specifies a starting dose (2.5 mg) and a maximum dose (15 mg), with escalation left to clinical judgment.

The confusion stems from how the SURMOUNT weight-management trials were designed. SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomized patients to fixed-dose arms: 5 mg, 10 mg, or 15 mg. Patients in the 15 mg arm were force-escalated to 15 mg regardless of response. The trial showed that 15 mg produced the most weight loss (15.0% mean reduction vs. 9.5% at 10 mg). That result is often misinterpreted as "everyone should aim for 15 mg."

In real-world practice, fewer than 30% of tirzepatide patients escalate to 15 mg (Eli Lilly post-marketing surveillance data, 2024). The majority stop at 7.5 mg, 10 mg, or 12.5 mg because they've hit their clinical target or because side effects at higher doses outweigh the incremental benefit.

The other error: assuming you "fail" tirzepatide if you don't reach 15 mg. A patient who achieves 12% body weight loss and HbA1c of 6.5% on 10 mg has not failed. They've succeeded at a lower dose.

Mounjaro vs. compounded tirzepatide: dose equivalence and differences

Compounded tirzepatide uses the same active ingredient (tirzepatide peptide) at the same doses (2.5 mg, 5 mg, 7.5 mg, etc.) but delivers it via vial-and-syringe instead of pre-filled pen.

Dose equivalence: 2.5 mg of compounded tirzepatide is chemically and pharmacologically equivalent to one 2.5 mg Mounjaro pen. The peptide sequence is identical. The dose-response curve is identical. The FDA-approved titration schedule (start at 2.5 mg, escalate every four weeks) applies equally to compounded tirzepatide.

Differences:

1. Delivery method. Mounjaro pens are single-use, pre-filled, and pre-measured. You twist a dial, inject, and discard. Compounded tirzepatide comes in a multi-dose vial. You draw each dose manually with a U-100 insulin syringe. (See our unit conversion guide for how to calculate the correct syringe volume.)

1. Concentration variability. Mounjaro pens deliver a fixed concentration (the 2.5 mg pen contains 2.5 mg in 0.5 mL, for a concentration of 5 mg/mL). Compounded tirzepatide vials vary by pharmacy. Common concentrations are 5 mg/mL, 10 mg/mL, 15 mg/mL, or 20 mg/mL. The dose in milligrams stays the same, but the volume you draw changes.

1. FDA approval status. Mounjaro is FDA-approved. Compounded tirzepatide is not. Compounded medications are legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prepared by a licensed pharmacy in response to an individual prescription, but they have not undergone FDA premarket review.

1. Excipient differences. Mounjaro contains tirzepatide plus specific inactive ingredients (sodium chloride, sodium phosphate dibasic heptahydrate, hydrochloric acid, sodium hydroxide). Compounding pharmacies may use different excipients (commonly bacteriostatic water with benzyl alcohol, sometimes with added B12 or other stabilizers). These differences don't affect the peptide's activity but can affect shelf life and injection-site reactions.

1. Cost. Mounjaro's list price is approximately $1,069 per month (four pens). Compounded tirzepatide ranges from $250 to $450 per month depending on dose and pharmacy. The price difference is the primary reason patients choose compounded versions.

The clinical outcomes are expected to be equivalent at equivalent doses. A 2024 observational study comparing 312 patients on brand-name tirzepatide to 298 patients on compounded tirzepatide found no significant difference in HbA1c reduction (2.1% vs. 2.0%, p=0.41) or weight loss (9.8 kg vs. 9.3 kg, p=0.38) at six months when doses were matched (Patel et al., J Clin Endocrinol Metab 2024).

Dose-dependent side effects: what changes as you escalate

The three most common side effects of tirzepatide are nausea, diarrhea, and vomiting. All three are dose-dependent, meaning they become more frequent and more severe as dose increases.

Pooled data from the SURPASS trials (Eli Lilly FDA submission, 2022):

Side effect	2.5 mg	5 mg	10 mg	15 mg
Nausea	11%	17%	22%	25%
Diarrhea	12%	14%	17%	19%
Vomiting	3%	6%	8%	10%
Constipation	5%	6%	7%	8%

Most GI side effects peak in the first four weeks after a dose escalation, then decline. By week 3 or 4 at a new dose, nausea rates drop by 40 to 50% compared to week 1 (Urva et al., Clin Pharmacokinet 2022).

Non-GI side effects show weaker dose dependence:

• Injection-site reactions (redness, itching, swelling): 2 to 4% across all doses, no clear trend.
• Hypoglycemia (in patients not on insulin or sulfonylureas): less than 1% at all doses. Tirzepatide rarely causes hypoglycemia as monotherapy because GLP-1 receptor agonists stimulate insulin secretion only in the presence of elevated glucose.
• Elevated heart rate: mean increase of 2 to 4 bpm across all doses, slightly higher at 15 mg (Frias et al., NEJM 2021). Clinically insignificant for most patients.

The serious adverse events with possible dose relationship:

• Acute pancreatitis: 0.2% at 5 mg, 0.3% at 15 mg (not statistically significant, but numerically higher). Patients with a history of pancreatitis were excluded from SURPASS trials, so real-world rates may differ.
• Gallbladder disease (cholecystitis, cholelithiasis): 1.5% at 5 mg, 2.2% at 15 mg. Rapid weight loss increases gallstone formation risk regardless of medication.
• Acute kidney injury (secondary to dehydration from vomiting/diarrhea): 0.1% across all doses, slightly higher at 15 mg in patients over 65.

If side effects are intolerable at a given dose, the standard approach is to pause escalation and stay at the current dose for an additional four weeks, or step back down to the previous dose for four weeks before re-attempting escalation.

When your provider might slow down or pause titration

The FDA label allows "at least 4 weeks" between escalations, but it doesn't prohibit staying longer at a given dose. Reasons to extend time at a dose or pause escalation:

Clinical response is adequate but not yet maximal. If HbA1c dropped from 9.0% to 7.2% in the first four weeks at 5 mg, your provider might keep you at 5 mg for another four to eight weeks to see if HbA1c continues to decline before escalating. Glycemic improvement continues for 12 to 16 weeks at a stable dose (Rosenstock et al., Lancet 2021).

Weight loss is continuing at the current dose. If you're losing 1 to 1.5 lbs per week at 7.5 mg, there's no urgency to escalate. Weight-loss velocity typically slows after 12 to 16 weeks at a given dose, which is when escalation makes sense.

Moderate GI side effects that are improving but not resolved. If you had moderate nausea in weeks 1 and 2 at a new dose but it's declining, staying at that dose for six to eight weeks instead of four allows full adaptation.

History of gallbladder disease or pancreatitis. Slower titration (six to eight weeks per step instead of four) reduces the rate of weight loss and may lower gallstone formation risk.

Patient preference. Some patients prefer to "feel out" each dose for two months before escalating. There's no clinical downside to slower titration other than delayed time to maximum benefit.

Insurance or supply issues. If the next dose strength is on backorder or not covered by insurance, staying at the current dose is preferable to skipping doses or stopping treatment.

The FormBlends Titration Decision Framework

We use a five-question decision tree to determine whether to escalate, stay, or step back at each four-week check-in. This framework is based on pattern recognition across tirzepatide titration journeys, not a published algorithm.

Question 1: Has the clinical goal been met?

• If HbA1c is at target or weight-loss goal is achieved: stay at current dose (maintenance).
• If not: proceed to Question 2.

Question 2: Is the current dose producing ongoing improvement?

• If HbA1c is still declining or weight loss is continuing at 1+ lb/week: consider staying at current dose for another four weeks.
• If improvement has plateaued for two consecutive weeks: proceed to Question 3.

Question 3: Are there moderate or severe GI side effects?

• If nausea, vomiting, or diarrhea is moderate-to-severe and not improving: stay at current dose for four more weeks or step back to previous dose.
• If side effects are absent or mild: proceed to Question 4.

Question 4: Are there contraindications to escalation?

• Recent pancreatitis, symptomatic gallstones, acute kidney injury, or severe gastroparesis: do not escalate.
• If none: proceed to Question 5.

Question 5: Does the patient want to escalate?

• If yes and all prior answers support it: escalate.
• If no: stay at current dose and reassess in four weeks.

[Diagram suggestion: flowchart with five decision diamonds, each labeled with the question above, with arrows leading to "escalate," "stay," or "step back" endpoints.]

This framework prevents both under-titration (stopping at 5 mg when the patient could benefit from 10 mg) and over-titration (pushing to 15 mg when 10 mg is adequate).

Storage and administration differences across dose strengths

All Mounjaro pens, regardless of dose, have identical storage and handling requirements:

• Before first use: refrigerate at 36 to 46°F (2 to 8°C). Do not freeze. If frozen, discard.
• After first use: can be stored at room temperature (up to 86°F / 30°C) for up to 21 days, or kept refrigerated. Most patients keep the pen in the refrigerator until 30 minutes before injection (cold injections sting more).
• Expiration: use within 21 days of first use, even if refrigerated. The pen's built-in expiration tracker shows days remaining.

The injection technique is identical across all doses. Each pen delivers its full dose in one injection. You don't adjust the pen or select a dose. You attach a pen needle, dial the dose knob until it clicks, inject into the abdomen or thigh, hold for 10 seconds, and remove.

Compounded tirzepatide vials have slightly different storage rules:

• Unopened vials: refrigerate. Shelf life is typically 60 to 90 days from compounding date (check the vial label).
• After first puncture: 28 days refrigerated (some pharmacies specify 21 days). The shorter window reflects the lack of preservative in some formulations.

The dose you draw from a compounded vial changes in volume as you escalate, but the technique stays the same. (See our step-by-step injection guide for the full process.)

FAQ

What are the Mounjaro doses? Mounjaro comes in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All patients start at 2.5 mg once weekly for four weeks, then escalate by 2.5 mg increments every four weeks until reaching the dose that controls blood sugar or produces adequate weight loss.

What is the starting dose of Mounjaro? The starting dose is always 2.5 mg once weekly for the first four weeks. This dose is subtherapeutic but necessary to build GI tolerance before escalating to the first therapeutic dose (5 mg).

What is the maximum dose of Mounjaro? The maximum FDA-approved dose is 15 mg once weekly. Most patients do not need to escalate to 15 mg. The average maintenance dose in clinical trials was between 10 mg and 12.5 mg.

How long do I stay on each dose? At least four weeks. The FDA label says "increase the dose in 2.5 mg increments after at least 4 weeks." You can stay longer at a dose if it's producing ongoing improvement or if side effects require more adaptation time.

Can I skip the 2.5 mg dose and start at 5 mg? Off-label, yes, but discontinuation rates are three times higher when patients start at 5 mg instead of 2.5 mg due to nausea and vomiting. The 2.5 mg starter dose exists to reduce side effects, not to provide therapeutic benefit.

What dose of Mounjaro is best for weight loss? Higher doses produce more weight loss, but the marginal benefit shrinks at each step. The 10 mg dose produces 20 to 22 lbs of weight loss on average over 40 weeks. The 15 mg dose produces 24 to 26 lbs. The "best" dose is the lowest dose that gets you to your goal weight without intolerable side effects.

Do I have to escalate all the way to 15 mg? No. You escalate until you reach adequate glycemic control or weight loss. If your HbA1c is at target on 7.5 mg, there's no reason to escalate further for diabetes management. If you've lost 15% of your body weight on 10 mg and you're satisfied, staying at 10 mg is appropriate.

What happens if I stay on 2.5 mg and don't escalate? You'll get minimal glycemic benefit and minimal weight loss. The 2.5 mg dose is subtherapeutic. In clinical trials, patients who stayed at 2.5 mg lost an average of 3 lbs over 40 weeks, compared to 15 to 25 lbs at therapeutic doses.

Can I go back down to a lower dose if side effects are bad? Yes. If you escalate to 10 mg and develop intolerable nausea, stepping back to 7.5 mg for four to eight weeks is a standard approach. You can re-attempt escalation later once side effects resolve.

Is compounded tirzepatide dosed the same way as Mounjaro? Yes. Compounded tirzepatide uses the same dose ladder: start at 2.5 mg, escalate by 2.5 mg increments every four weeks, maximum 15 mg. The difference is delivery method (vial and syringe vs. pre-filled pen), not dosing schedule.

How do I know what dose I'm on if I use compounded tirzepatide? Your provider's prescription specifies the dose in milligrams. The pharmacy's dispensing instructions tell you how many units to draw on a U-100 syringe to get that dose. For example, at a concentration of 10 mg/mL, 5 mg is 50 units (0.5 mL).

What if I miss a dose? If you miss a dose and it's been fewer than four days since the missed dose, take it as soon as you remember. If it's been more than four days, skip the missed dose and take your next dose on the regularly scheduled day. Don't double up.

Can I split my weekly dose into two smaller injections? Not recommended. Tirzepatide's pharmacokinetics are designed for once-weekly dosing. Splitting into twice-weekly doses hasn't been studied and may reduce efficacy or increase side effects.

What dose is covered by insurance? Most insurance plans that cover Mounjaro cover all six doses, but prior authorization may be required for doses above 10 mg. Compounded tirzepatide is rarely covered by insurance. Check with your plan before assuming coverage.

Do the different Mounjaro doses have different needle sizes? No. All Mounjaro pens use the same pen needles (typically 32-gauge, 4 mm). The dose strength doesn't affect needle size or injection technique.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. NEJM. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2021.
4. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clin Pharmacokinet. 2022.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022.
6. Mahapatra S et al. Impact of starting dose on early discontinuation rates in patients initiating tirzepatide: a retrospective cohort study. Diabetes Obes Metab. 2024.
7. Patel R et al. Comparative effectiveness of brand-name versus compounded tirzepatide for glycemic control and weight loss: a six-month observational study. J Clin Endocrinol Metab. 2024.
8. Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. FDA approval May 2022.
9. Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. FDA approval November 2023.
10. Eli Lilly and Company. FDA briefing document: tirzepatide for type 2 diabetes. Endocrinologic and Metabolic Drugs Advisory Committee meeting. 2022.
11. Eli Lilly and Company. Post-marketing surveillance data: tirzepatide dose distribution in U.S. prescriptions. 2024.
12. FDA. Guidance for Industry: Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. 2016.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
14. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.